Back to Authors

Diab, Rawan

Mayo Clinic

American University of Beirut

Citations 2

Polymyalgia rheumatica following respiratory syncytial virus (RSV) vaccination
Labban, Mohamad El , Oluic, Stevan , Guleid, Hussein, Diab, Rawan, Rida, Mohamad Ali , El Labban, Mohamad, Hassan, Mohamed Sayed

European Journal of Case Reports in Internal Medicine | June 28, 2024 | Volume: 11 | Issue: 7 | Pages: No page available

10.12890/2024_004636 Get It

Introduction: Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder that causes stiffness and pain in the proximal joints, including the shoulders, hips and neck. The exact cause of polymyalgia rheumatica is yet to be fully understood, but research suggests that both genetic and environmental factors may contribute to it. Studies have previously linked the onset and relapse of polymyalgia rheumatica symptoms to the influenza and COVID-19 vaccines. The Food and Drug Administration approved the respiratory syncytial virus (RSV) vaccine, which is a recombinant protein vaccine for adults over 60, in May 2023. No previous reports of polymyalgia rheumatica onset or relapse have been linked to the RSV vaccine. The human proteome shares some peptides with the RSV F antigen, suggesting a high risk of cross-reactivity when using that antigen in vaccination formulations. Case description: A 72-year-old man experienced a new onset of bilateral shoulder pain and stiffness three days after receiving the Abrysvo® RSV vaccine. The symptoms lasted more than an hour (up until noon) and interfered with his activities of daily living. Inflammatory markers such as C-reactive protein were elevated. The patient’s symptoms and inflammatory marker levels significantly improved with prednisone therapy. Conclusion: In patients with typical PMR symptoms, it is important for clinicians to carefully review immunisation history to rule out any potentially related adverse effects.
Advanced cross-sectional imaging of cerebral aneurysms
Diab, Rawan, Chang, Dandan, Levitt, Michael R. , Aksakal, Mehmet , Zhao, Huilin , Romero-Sánchez, Griselda , Mossa‐Basha, Mahmud , Huynh, Thien J, Mossa-Basha, Mahmud , Levitt, Michael R , Chang, Dandan, Zhu, Chengcheng , Huynh, Thien

The British Journal of Radiology | November 18, 2022 | Volume: 96 | Issue: 1141 | Pages: No page available

10.1259/bjr.20220686 Get It

While the rupture rate of cerebral aneurysms is only 1% per year, ruptured aneurysms are associated with significant morbidity and mortality, while aneurysm treatments have their own associated risk of morbidity and mortality. Conventional markers for aneurysm rupture include patient-specific and aneurysm-specific characteristics, with the development of scoring systems to better assess rupture risk. These scores, however, rely heavily on aneurysm size, and their accuracy in assessing risk in smaller aneurysms is limited. While the individual risk of rupture of small aneurysms is low, due to their sheer number, the largest proportion of ruptured aneurysms are small aneurysms. Conventional imaging techniques are valuable in characterizing aneurysm morphology; however, advanced imaging techniques assessing the presence of inflammatory changes within the aneurysm wall, hemodynamic characteristics of blood flow within aneurysm sacs, and imaging visualization of irregular aneurysm wall motion have been used to further determine aneurysm instability that otherwise cannot be characterized by conventional imaging techniques. The current manuscript reviews conventional imaging techniques and their value and limitations in cerebral aneurysm characterization, and evaluates the applications, value and limitations of advanced aneurysm imaging and post-processing techniques including intracranial vessel wall MRA, 4D-flow, 4D-CTA, and computational fluid dynamic simulations.